Colorectal cancer: Review of signaling pathways and associated therapeutic strategies

被引：6

作者：

Leiphrakpam, Premila D. ^{[1
,2
]}

Rajappa, Senthil J. ^{[3
]}

Krishnan, Mridula ^{[4
]}

Batra, Rishi ^{[5
]}

Murthy, Shilpa S. ^{[6
]}

Are, Chandrakanth ^{[1
,2
,7
]}

机构：

[1] Univ Nebraska Med Ctr, Coll Med, Grad Med Educ, Omaha, NE USA

[2] Univ Nebraska Med Ctr, Coll Med, Dept Surg, Div Surg Oncol, Omaha, NE USA

[3] Basavatarakam Indo Amer Canc Hosp, Med Oncol, Hyderabad, Telangana, India

[4] Univ Nebraska Med Ctr, Coll Med, Dept Internal Med, Div Oncol & Hematol, Omaha, NE USA

[5] Univ Nebraska Med Ctr, Coll Med, Dept Surg, Div Gen Surg, Omaha, NE USA

[6] Mem Sloan Kettering Canc Ctr, Div Surg Oncol, Global Canc Dispar Initiat, New York, NY USA

[7] Univ Nebraska Med Ctr, Coll Med, Dept Surg, Div Surg Oncol, Omaha, NE 68198 USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2023年 / 127卷 / 08期

关键词：

biomarkers; colorectal cancer; targeted therapy; RANDOMIZED PHASE-III; FOLFIRI PLUS BEVACIZUMAB; MOLECULAR SUBGROUP ANALYSES; FACTOR-BETA RECEPTOR; KRAS WILD-TYPE; OPEN-LABEL; 1ST-LINE TREATMENT; FOLFOXIRI PLUS; DOUBLE-BLIND; MAINTENANCE TREATMENT;

D O I：

10.1002/jso.27295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor profiling and targeted therapy revolutionized the treatment strategies of metastatic colorectal cancer (mCRC) in the last decade. The heterogeneity of CRC tumors plays a critical role in the development of treatment resistance, which underscores the need to understand the molecular mechanism involved in CRC to develop novel targeted therapeutic strategies. This review provides an overview of the signaling pathways driving CRC, the existing targeted agents, their limitations, and future trends.

引用

页码：1277 / 1295

页数：19